Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dimitrios A Pappas

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
ACR Open Rheumatology|February 11, 2021
Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis RegistryJoel M Kremer, Clifton O Bingham, Laura C Cappelli, et al.
Pharmacoepidemiology and Drug Safety|August 26, 2015
Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approachFredrik Nyberg, Johan Askling, Niklas Berglind, et al.
Rheumatology and Therapy|June 20, 2021
A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational StudyStanley Cohen, Alvin F Wells, Jeffrey R Curtis, et al.
Arthritis Care & Research|July 24, 2015
Methodological Challenges When Comparing Demographic and Clinical Characteristics of International Observational RegistriesSuzanne M M Verstappen, Johan Askling, Niklas Berglind, et al.
Annals of the Rheumatic Diseases|December 2, 2015
How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registriesJohan Askling, Niklas Berglind, Stefan Franzen, et al.
Annals of the Rheumatic Diseases|February 10, 2016
Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular diseaseKaleb Michaud, Niklas Berglind, Stefan Franzén, et al.
RMD Open|October 31, 2017
Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programmeHisashi Yamanaka, Johan Askling, Niklas Berglind, et al.
Rheumatology (Oxford, England)|December 28, 2018
Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritisJeffrey R Curtis, Darl D Flake, Michael E Weinblatt, et al.
Clinical Rheumatology|April 27, 2018
Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional studyDimitrios A Pappas, Fredrik Nyberg, Joel M Kremer, et al.
Arthritis Research & Therapy|October 25, 2019
Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factorVictor Farutin, Thomas Prod'homme, Kevin McConnell, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
ACR Open Rheumatology|February 11, 2021
Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis RegistryJoel M Kremer, Clifton O Bingham, Laura C Cappelli, et al.
Pharmacoepidemiology and Drug Safety|August 26, 2015
Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approachFredrik Nyberg, Johan Askling, Niklas Berglind, et al.
Rheumatology and Therapy|June 20, 2021
A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational StudyStanley Cohen, Alvin F Wells, Jeffrey R Curtis, et al.
Arthritis Care & Research|July 24, 2015
Methodological Challenges When Comparing Demographic and Clinical Characteristics of International Observational RegistriesSuzanne M M Verstappen, Johan Askling, Niklas Berglind, et al.
Annals of the Rheumatic Diseases|December 2, 2015
How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registriesJohan Askling, Niklas Berglind, Stefan Franzen, et al.
Annals of the Rheumatic Diseases|February 10, 2016
Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular diseaseKaleb Michaud, Niklas Berglind, Stefan Franzén, et al.
RMD Open|October 31, 2017
Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programmeHisashi Yamanaka, Johan Askling, Niklas Berglind, et al.
Rheumatology (Oxford, England)|December 28, 2018
Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritisJeffrey R Curtis, Darl D Flake, Michael E Weinblatt, et al.
Clinical Rheumatology|April 27, 2018
Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional studyDimitrios A Pappas, Fredrik Nyberg, Joel M Kremer, et al.
Arthritis Research & Therapy|October 25, 2019
Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factorVictor Farutin, Thomas Prod'homme, Kevin McConnell, et al.
Pageof 8